Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
InnoCare Pharma Limited (9969.HK)
Beijing, CN
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.65% | -3.41% | -15.91% | -3.80% | -21.52% | -5.45% | +3.29% | +55.48% | -51.03% | +18.55% | +18.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | +1 |
| Buy | 11 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+127.6% ★ Q1'26: +37.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+238.5% ★ Q1'26: +495.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-8.3% Q1'26: -0.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+19.2% ★ Q1'26: +12.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+21.4% ★ Q1'26: +12.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.2% Q1'26: -1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.90× ★ Q1'26: 6.72× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 3 EPS Ana. |
Dec 2027 10 Rev. Ana. 5 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.36M
est: 14.94M (-90.9%)
|
1.04B
est: 1.24B (-16.0%)
|
625.40M
est: 689.68M (-9.3%)
|
738.54M
est: 726.23M (+1.7%)
|
1.01B
est: 986.42M (+2.3%)
|
2.30B
est: 2.08B (+10.7%)
|
2.36B
2.09B – 2.61B
+13.9% YoY
|
2.98B
2.66B – 3.35B
+26.0% YoY
|
3.76B
3.34B – 4.19B
+26.2% YoY
|
| EBITDA |
-556.92M
est: -9.39M (-5,830.8%)
|
16.23M
est: -16.80B (+100.1%)
|
-808.28M
est: -140.65B (+99.4%)
|
-516.55M
est: -276.12M (-87.1%)
|
-463.49M
est: -8.50T (+100.0%)
|
555.89M
est: -789.00M (+170.5%)
|
-898.85M
-992.87M – -795.22M
-13.9% YoY
|
-1.13B
-1.27B – -1.01B
-26.0% YoY
|
-1.43B
-1.59B – -1.27B
-26.2% YoY
|
| EBIT |
-558.99M
est: -10.03M (-5,471.4%)
|
-17.48M
est: -16.91B (+99.9%)
|
-876.68M
est: -141.59B (+99.4%)
|
-609.18M
est: -314.66M (-93.6%)
|
-521.47M
est: -8.56T (+100.0%)
|
440.59M
est: -899.13M (+149.0%)
|
-1.02B
-1.13B – -906.22M
-13.9% YoY
|
-1.29B
-1.45B – -1.15B
-26.0% YoY
|
-1.63B
-1.82B – -1.45B
-26.2% YoY
|
| Net Income |
-391.40M
est: -792.72M (+50.6%)
|
-64.55M
est: -16.85B (+99.6%)
|
-886.59M
est: -867.46M (-2.2%)
|
-631.26M
est: -438.03M (-44.1%)
|
-440.63M
est: -190.54M (-131.2%)
|
625.84M
est: 243.92M (+156.6%)
|
168.15M
48.12M – 288.71M
-31.1% YoY
|
162.70M
131.42M – 306.65M
-3.2% YoY
|
443.97M
307.50M – 538.11M
+172.9% YoY
|
| SGA |
113.15M
est: 253.10M (-55.3%)
|
344.66M
est: 527.97M (-34.7%)
|
489.61M
est: 11.69B (-95.8%)
|
252.13M
est: 301.42M (-16.4%)
|
310.64M
est: 409.41M (-24.1%)
|
718.67M
est: 861.29M (-16.6%)
|
981.21M
868.08M – 1.08B
+13.9% YoY
|
1.24B
1.10B – 1.39B
+26.0% YoY
|
1.56B
1.39B – 1.74B
+26.2% YoY
|
| EPS |
-0.40
est: -0.47 (+14.7%)
|
-0.05
est: 0.00 (-1,280.3%)
|
-0.60
est: -0.50 (-20.6%)
|
-0.37
est: -0.26 (-41.9%)
|
-0.26
est: -0.29 (+10.1%)
|
0.36
est: 0.14 (+160.7%)
|
0.10
0.03 – 0.16
-30.8% YoY
|
0.12
0.07 – 0.17
+30.1% YoY
|
0.28
0.17 – 0.31
+122.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 1.12% | 724.8K | 0.59% |
| 2 | Global X - Aging Population ETF AGNG | 0.28% | 235.7K | 0.50% |
| 3 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.20% | 757.0K | 0.47% |
| 4 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.20% | 752.8K | 0.50% |
| 5 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.17% | 205.9K | 0.42% |
| 6 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.15% | 107.0K | 0.74% |
| 7 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.11% | 564.3K | 0.32% |
| 8 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.10% | 600.6K | 0.55% |
| 9 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.10% | 366.8K | 0.72% |
| 10 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.09% | 329.8K | 0.74% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jisong Cui | Co-Founder, Chairwoman & Chief Executive Officer | 10M | — |
| Renbin Zhao | Senior Vice President of Clinical Development & Medical Research and Executive Director | 4M | — |
| John Zhou | C.M.O | — | — |
| Junjian Liu | Senior Vice President of Biology & Biologics | — | — |
| Junsu Wang | General Counsel | — | female |
| Nan Gao | Chief Operating Officer | — | male |
| Xiangyang Chen | Chief Technology Officer | — | — |
| Xin Fu | Chief Financial Officer | — | male |
| Davy Ouyang | Vice President & Head of Biology | — | male |
| Yue Tan | Accounting Supervisor | — | — |
| Jeff Chen | Chief Commercial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9969.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
